Clinical trial · Interventional
Hyperthermia With Flexible Electrode-typed 2-MHz Device During Radiotherapy for Solid Tumors
Exploratory, Open-labelled, Control Group-included, Single Institution Clinical Trial for Evaluating Immunogenic Effect of Hyperthermia Applied With Flexible Electrode-typed 2-MHz Device During Radiotherapy for Solid Tumors
NCT05282784CI-TRIAL-00057141unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of this study is to evaluate immunogenic effect of hyperthermia applied with flexible electrode-typed 2-MHz device during radiotherapy for solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hyperthermia | Other | — | UNRESOLVED |
| Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Hyperthermia group
- description
- Hyperthermia Radiotherapy
- interventionNames
- Other: Hyperthermia
- Radiation: Radiotherapy
- type
- ACTIVE_COMPARATOR
- label
- Control
- description
- Radiotherapy
- interventionNames
- Radiation: Radiotherapy
Primary outcomes (1)
- measure
- Immunogenic effect
- timeFrame
- 1 weeks after treatment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Solid tumor (primary, metastatic) * Eastern Cooperative Oncology Group (ECOG) score 0-3 * Ability to understand and the willingness to sign a written informed consent documents Exclusion Criteria: * Myocardial infarct, unstable angina, heart failure, uncontrolled arrhythmia within 6 months * Active infectious disease * Pregnant or probability of pregnancy during treatment * Obesity (BMI ≥35) * Immunosuppressive drug after organ transplantation * Autoimmune disease * Skin injury on treatment area
References
Publications (0)
Data not yet available
No reference posted for this study.